These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33257497)

  • 41. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
    Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
    Sultan N; Pope JE; Clements PJ;
    Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.
    Chakravarty EF; Martyanov V; Fiorentino D; Wood TA; Haddon DJ; Jarrell JA; Utz PJ; Genovese MC; Whitfield ML; Chung L
    Arthritis Res Ther; 2015 Jun; 17(1):159. PubMed ID: 26071192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disease activity indices in systemic sclerosis: a systematic literature review.
    Melsens K; De Keyser F; Decuman S; Piette Y; Vandecasteele E; Smith V
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):186-192. PubMed ID: 27385265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision.
    Studenic P; Aletaha D; de Wit M; Stamm TA; Alasti F; Lacaille D; Smolen JS; Felson DT
    Ann Rheum Dis; 2023 Jan; 82(1):74-80. PubMed ID: 36280238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).
    Yazici Y; Curtis JR; Ince A; Baraf HS; Lepley DM; Devenport JN; Kavanaugh A
    Clin Exp Rheumatol; 2013; 31(3):358-64. PubMed ID: 23305631
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
    Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
    Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
    Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
    Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
    Allanore Y; Wung P; Soubrane C; Esperet C; Marrache F; Bejuit R; Lahmar A; Khanna D; Denton CP;
    Ann Rheum Dis; 2020 Dec; 79(12):1600-1607. PubMed ID: 32963047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
    Gordon JK; Martyanov V; Franks JM; Bernstein EJ; Szymonifka J; Magro C; Wildman HF; Wood TA; Whitfield ML; Spiera RF
    Arthritis Rheumatol; 2018 Feb; 70(2):308-316. PubMed ID: 29073351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.
    Quillinan NP; McIntosh D; Vernes J; Haq S; Denton CP
    Ann Rheum Dis; 2014 Jan; 73(1):56-61. PubMed ID: 24067785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology.
    van Gestel AM; Anderson JJ; van Riel PL; Boers M; Haagsma CJ; Rich B; Wells G; Lange ML; Felson DT
    J Rheumatol; 1999 Mar; 26(3):705-11. PubMed ID: 10090187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
    Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
    Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.
    Amjadi S; Maranian P; Furst DE; Clements PJ; Wong WK; Postlethwaite AE; Khanna PP; Khanna D;
    Arthritis Rheum; 2009 Aug; 60(8):2490-8. PubMed ID: 19644851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
    Khanna D; Denton CP; Jahreis A; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Lafyatis R; Stifano G; Spotswood H; Chen-Harris H; Dziadek S; Morimoto A; Sornasse T; Siegel J; Furst DE
    Lancet; 2016 Jun; 387(10038):2630-2640. PubMed ID: 27156934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
    Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
    Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial.
    Zhou J; Yang D; Zhou SH; Wang JP; Liu YS; Wang SL
    Chin J Integr Med; 2018 Mar; 24(3):185-192. PubMed ID: 28197938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.